Quidel

Quidel Net Debt per Share

The Net Debt per Share of Quidel (QDEL) as of Nov 5, 2026 is 36.47 USD. In the previous year, Net Debt per Share was 35.56 USD — a change of 2.54% (higher).

Net Debt per Share

36.47USD

YoY

2.54%

Last updated:

Net Debt per Share of Quidel is 2025 36.47 USD. Net Debt per Share of Quidel was 2024 35.56 USD. It decreases by 2.54% higher compared to the previous year.

The Quidel Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
0.94 USD
Jan 1, 2019
-0.52 USD
Jan 1, 2020
-7.21 USD
Jan 1, 2021
-12.20 USD
Jan 1, 2022
34.12 USD
Jan 1, 2023
33.08 USD
Jan 1, 2024
35.56 USD
Jan 1, 2025
36.47 USD
The Quidel Net Debt per Share history
YEARNet Debt per ShareYoY
36.47USD+2.54%
35.56USD+7.50%
33.08USD-3.04%
34.12USD-379.75%
-12.20USD+69.10%
-7.21USD+1,288.92%
-0.52USD-155.20%
0.94USD-82.31%
5.32USD-1,811.74%
-0.31USD-51.55%
-0.64USD-24.61%
-0.85USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quidel Stock analysis

What does Quidel do? Quidel Corporation is a US-based company specializing in the production of rapid tests for medical diagnostics. It was founded in 1979 and is headquartered in San Diego, California. Since 1991, it has been listed on the NASDAQ stock exchange. Quidel initially started as Diagnostic Reagents Laboratory (DRL) and focused on manufacturing diagnostic products for the veterinary sector. In 1990, it was renamed Quidel Corporation and expanded its operations into human diagnostics. The company's business model revolves around the development and production of immunological rapid tests that can quickly and easily diagnose infectious diseases and other health problems. Quidel focuses on creating high-quality, accurate, and cost-effective test procedures that can be used by healthcare professionals or even laypersons at home. One of Quidel's core competencies is bringing to market rapid tests that are easy to perform and provide immediate results without the need to send samples to a laboratory. The company offers a wide range of rapid tests for diagnosing various diseases. These include tests for infectious diseases such as influenza, streptococcus, Lyme disease, and chlamydia, as well as tests for pregnancy, drug abuse, and cardiovascular diseases. The tests are available as single tests or panel tests that can diagnose multiple diseases simultaneously. Quidel operates in four business segments: Molecular Diagnostics, Point-of-Care Diagnostics, Immunoassays, and Specialized Diagnostic Solutions. The Molecular Diagnostics segment focuses on developing molecular diagnostic tests and instruments for laboratory use. The Point-of-Care Diagnostics segment develops and produces rapid tests for use in medical practices and hospitals. The Immunoassays segment specializes in reagent-based tests for the quantitative analysis of biomolecules. The Specialized Diagnostic Solutions segment includes specialized diagnostic products, such as test systems for monitoring antibiotic therapies. In conclusion, Quidel Corporation specializes in the development and production of rapid tests for medical diagnostics. The company offers a wide range of high-quality, accurate, and cost-effective test procedures for diagnosing infectious diseases, pregnancy, drug abuse, and cardiovascular diseases. Quidel has gained a significant market share in the diagnostics field through its rapid tests and diverse range of test panels for various conditions, and it is known for its innovative products. Quidel is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quidel stock

Net Debt per Share of Quidel is 36.47 USD in 2025.

Net Debt per Share of Quidel changed from 35.56 USD to 36.47 USD, representing a 2.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Quidel since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Quidel

All Key Metrics — Quidel